Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA)

March 20, 2024 updated by: University of Arkansas

Recruiting will be performed via checking the calendar for scheduled TKA procedures in the > 8 weeks by clinical staff in the UAMS orthopedic clinic. Clinic staff will look for basic inclusion/exclusion criteria in the EMR for those patients. Clinic staff will either contact directly or send contact information to the PI of this study to contact for recruitment purposes. During the initial phone call, study staff will review inclusion/exclusion criteria to verify eligibility and will discuss study specifics and send a link to the current informed consent form located on the UAMS REDCap server. If the subject wishes to enroll, they will do so via electronic consent through REDCap. REDCap will notify study staff that the consent was signed, then study staff will schedule initial baseline study visit.

Visit 1 and Visit 2 will take place at the RIOA at week 0 and week 24, respectively. Participants will report having fasted overnight, and having abstained from alcohol for 24 hours, vigorous exercise for 24 hours, and caffeine for 12 hours. A blood sample will be drawn upon arrival, followed by a DXA scan to measured bone mineral density (BMD) in both hips and lumbar spine, and for body composition, using CTRAL equipment. Participants will also undergo a body water assessment using BIA to determine deuterium dose. Bilateral handgrip strength will be measured via Dynamometer. Participants will fill out a 3-Day food log, physical activity questionnaire, pain scale, KOOS, VR-12, and the POMS. Participants will be given an 8-week supply of their respective treatment supplement, with instructions and a compliance log (to be filled out monthly). Participants will also be given their dose of deuterium oxide (D2O) to be ingested according to instruction at week 2&3, prior to TKA (week 4).

Tissue samples for ACL, bone fragments, and synovial fluid will be collected by the PI during TKA surgery. All other assessments will be taken during clinical visits with the participant's physical therapists and their orthopedic doctors. The PI will attend some of these visits to assess wound healing, administer handgrip strength assessment, and to replenish participant treatment supply.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

UAMS Orthopedic Clinic personnel will monitor the clinic logs for prospective participants meeting the inclusion/exclusion criteria of the study, notifying the study Principal Investigator (PI) of potential study participants. The PI will meet with the with interested participant to obtain consent virtually (via REDCap) prior to scheduling baseline visit (week 0) at the UAMS Reynolds Institute on Aging (RIOA). The potential study participant will be allowed as much time as needed to be comfortable in their decision to participate in the study.

For tissue specimen collection during TKA, the PI will attend the surgery, collecting samples of the ACL, synovial fluid and bone fragments as they are removed (and would otherwise be discarded) by the surgeon. Blood will also be collected by the anesthesiologist after line placement in the operating room. Tissue samples will be prepared as described in the Specimen Handling and Storage Section and taken to the PI's laboratory, the Center for Translational Research in Aging and Longevity (CTRAL) located on the 7th floor of the UAMS RIOA (a secured access floor).

Study Visits Week 0 (Baseline)

  • Informed Consent (executed electronically)
  • Randomization (Excel Randomization Function)
  • Baseline assessments (CTRAL) Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Physical Activity Pain Dietary Intake (3-Day Food Log) Dual-energy X-ray absorptiometry (DXA) scan - bone density (both hips and lumbar spine) Dual-energy X-ray absorptiometry (DXA) scan - body composition Bioelectrical impedance analysis (BIA) Scan - body water Hand grip strength Collecting blood sample (4 mL x 1 for serum and 4 mL x 1 for plasma)
  • Treatment 10 g Collagen Peptides or Placebo, Weeks 0 - 24 Deuterated water (D2O), Weeks 6 - 8 Week 4
  • Virtual
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)
  • Veterans RAND 12 (VR-12)
  • Profile of Mood States (POMS)
  • Physical Activity
  • Pain 3-day food log Compliance Week 8
  • Virtual
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)
  • Veterans RAND 12 (VR-12)
  • Profile of Mood States (POMS)
  • Physical Activity
  • Pain 3-day food log Compliance
  • Total Knee Arthroplasty Collect Anterior Cruciate Ligament Collect Synovial Fluid Collect blood sample (4 mL x 1 for serum and 4 mL x 1 for plasma)
  • Physical Therapy (three times weekly, Weeks 8 - 24) Pain Range of Motion (ROM) for flexion and extension of surgery knee KOOS Jr. Week 10
  • Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 12
  • Virtual
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)
  • Veterans RAND 12 (VR-12)
  • Profile of Mood States (POMS)
  • Physical Activity
  • Pain 3-day food log Compliance Week 14
  • Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 16
  • Virtual
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)
  • Veterans RAND 12 (VR-12)
  • Profile of Mood States (POMS)
  • Physical Activity
  • Pain 3-day food log Compliance
  • Physical Therapy Follow Up Pain ROM KOOS Jr. Functional Measures Battery Week 20
  • Virtual
  • Knee Injury and Osteoarthritis Outcome Score (KOOS)
  • Veterans RAND 12 (VR-12)
  • Profile of Mood States (POMS)
  • Physical Activity
  • Pain 3-day food log Compliance
  • Physician Visit Wound healing Pain ROM for flexion and extension of surgery knee Grip Strength Week 24 (Final Assessments - Stop Treatment)
  • CTRAL Knee Injury and Osteoarthritis Outcome Score (KOOS) Veterans RAND 12 (VR-12) Profile of Mood States (POMS) Pain Activity DXA - bone mineral density (both hips and lumbar spine) DXA - body composition Grip Strength Compliance 3-Day Food Log

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Males and Females, 50 to 75 years old
  • With a body mass index of 20.0 to 39.9 kg/m2
  • Diagnosed with primary osteoarthritis
  • Scheduled for a TKA at UAMS (two months prior to surgery) at UAMS
  • Live near Little Rock and scheduled to attend physical therapy in Little Rock
  • COVID-19 negative and/or asymptomatic.

Exclusion Criteria:

  • Previously sustained serious knee injury or surgery to ACL in TKA knee
  • Females not postmenopausal
  • Having undergone hormone replacement therapy in the last 12 months.
  • Active diagnosis of blood borne infectious disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Collagen Peptides
10 grams per day for 24 weeks
Dietary supplement: SOLUGEL
Bovine collagen peptide supplement
Other Names:
  • CP
Placebo Comparator: Placebo
10 grams per day maltodextrin for 24 weeks
Dietary supplement: Placebo
Maltodextrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of pre-surgical supplementation on mRNA transcription
Time Frame: 2 months after supplementation
Measuring mRNA in the anterior cruciate ligament extracted during surgery
2 months after supplementation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Arkansas

Collaborators

Tessenderlo Group

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2024

Primary Completion (Estimated)

June 1, 2025

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

April 10, 2023

First Submitted That Met QC Criteria

April 10, 2023

First Posted (Actual)

April 21, 2023

Study Record Updates

Last Update Posted (Actual)

March 21, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 275656

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe